HOUSTON, April 22, 2020 /PRNewswire/ -- Moleculin Biotech,
Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical
stage pharmaceutical company with a broad portfolio of drug
candidates, today announced that it has welcomed Dr. Richard Whitley to its Science Advisory Board to
guide its development strategy for WP1122 for the potential
treatment of COVID-19 and other viral diseases.
"Our development effort to get WP1122 into a clinical trial with
COVID-19 patients is now getting into high gear," commented
Walter Klemp, Chairman and CEO of
Moleculin. "Among his many accomplishments, Dr. Whitley leads
the Drug Discovery and Development Center for the National
Institute of Allergy and Infectious Diseases, making him one of the
Nation's leading authorities on the clinical development of
antiviral therapies."
Richard Whitley, M.D., is a
Distinguished Professor of Pediatrics, Professor of Microbiology,
Medicine and Neurosurgery; Loeb Eminent Scholar Chair in
Pediatrics; Co-Director, Division of Pediatric Infectious Diseases;
Vice-Chair, Department of Pediatrics; Senior Scientist, Department
of Gene Therapy; Scientist, Cancer Research and Training Center;
Faculty, Gene Therapy Center; Associate Director for Drug Discovery
and Development and Senior Leader, Pediatric Oncology Program,
O'Neal Comprehensive Cancer Center at the University of Alabama at Birmingham (UAB); and
Co-Founder and Co-Director, Alabama Drug Discovery Alliance.
Dr. Whitley is responsible for the National Institute of Allergy
and Infectious Diseases Collaborative Antiviral Study Group whose
role is to perform clinical trials of antiviral therapies directed
against medically important viral diseases of children and adults
including viruses considered as threats to human health. He has
published more than 347 articles. He participates in numerous Data
Safety and Monitoring Boards for ongoing clinical studies. He is a
past President of the Infectious Diseases Society of America and
received the UAB President's Medal in 2007. In 2013, he was named
as the inaugural recipient of the Distinguished Clinical Research
Scholar and Educator in Residence at the NIH Clinical Center.
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical stage pharmaceutical
company focused on the development of a broad portfolio of oncology
drug candidates for the treatment of highly resistant tumors and
viruses. The Company's clinical stage drugs are: Annamycin, a Next
Generation Anthracycline designed to avoid multidrug resistance
mechanisms with little to no cardiotoxicity, being studied for the
treatment of relapsed or refractory acute myeloid leukemia, more
commonly referred to as AML; WP1066, an Immune/Transcription
Modulator capable of inhibiting p-STAT3 and other oncogenic
transcription factors while also stimulating a natural immune
response, under investigation for brain tumors, pancreatic cancer
and hematologic malignancies; and WP1220, an analog to WP1066,
being developed for the topical treatment of cutaneous T-cell
lymphoma. Moleculin is also engaged in preclinical development of
additional drug candidates, including additional
immune/transcription modulators, as well as WP1122, a compound
capable of metabolism/glycosylation disruption.
For more information about the Company, please
visit http://www.moleculin.com.
Forward-Looking Statements
Some of the statements in this release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. Forward-looking statements in this press
release include, without limitation, the ability of WP1122 to
demonstrate safety and efficacy in humans. Although Moleculin
believes that the expectations reflected in such forward-looking
statements are reasonable as of the date made, expectations may
prove to have been materially different from the results expressed
or implied by such forward-looking statements. Moleculin Biotech
has attempted to identify forward-looking statements by terminology
including ''believes,'' ''estimates,'' ''anticipates,''
''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,''
''may,'' ''could,'' ''might,'' ''will,'' ''should,''
''approximately'' or other words that convey uncertainty of future
events or outcomes to identify these forward-looking statements.
These statements are only predictions and involve known and unknown
risks, uncertainties, and other factors, including those discussed
under Item 1A. "Risk Factors" in our most recently filed Form 10-K
filed with the Securities and Exchange Commission ("SEC") and
updated from time to time in our Form 10-Q filings and in our other
public filings with the SEC. Any forward-looking statements
contained in this release speak only as of its date. We undertake
no obligation to update any forward-looking statements contained in
this release to reflect events or circumstances occurring after its
date or to reflect the occurrence of unanticipated events. The
Company cautions investors not to place undue reliance on the
interim results announced today.
Contacts
James Salierno
/ Carol Ruth
The Ruth Group
646-536-7028 /
7000
jsalierno@theruthgroup.com
cruth@theruthgroup.com
View original
content:http://www.prnewswire.com/news-releases/moleculin-announces-head-of-niaid-antiviral-drug-discovery-and-development-center-joins-covid-19-drug-development-team-301044999.html
SOURCE Moleculin Biotech, Inc.